Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BH006 vs Fosaprepitant + Palonosetron in Healthy Subjects
NCT06427681Phase 1Not yet recruiting
- Sponsor
- Zhuhai Beihai Biotech
- Start
- May 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BH006 in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Zhuhai Beihai Biotech. Primary endpoints: Area Under the Curve From Time 0 to Last Quantifiable Concentration, Area Under the Curve From Time 0 to Infinity and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
BH006
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06427681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427681.